(10 \g=m\mol/l) was unaffected by the steroid, although readily antagonised (P<0\m=.\01)by nifedipine (1\p=n-\100 \g=m\mol/l). Inclusion of actinomycin D (1\m=.\78\g=m\mol/l) or cycloheximide (0\m=.\8\g=m\mol/l), inhibitors of RNA and protein synthesis respectively, in the medium effectively abrogated the inhibitory effects of dexamethasone (0\m=.\1\g=m\mol/l) on the secretory responses to TRH (10 nmol/l), VIP (10 nmol/l) and forskolin (100 \g=m\mol/l). pool. Progesterone (0\m=.\1\g=m\mol/l) and aldosterone ( 0\ m=. \ 1 \g=m\mol/l) were also weakly active in this regard, but thyroxine and tri-iodothyronine (0\ m=. \ 1 \g=m\mol/l) were not. Addition of an N-terminal LC1 fragment, LC1(1\p=n-\188)(0\ m=. \ 05\ p=n-\ 0\ m=. \ 53pmol/l) to the incubation medium reduced significantly (P<0\m=.\01) the increases in irTSH release induced by TRH (10 nmol/l), VIP (10 nmol/l) and forskolin (100 \ g = m\ mo l / l ) , but failed to influence (P<0\m=.\05) those initiated by BAY K8644 (10 \g=m\mol / 1). Furthermore, the inhibitory actions of dexamethasone (0\m=.\1\g=m\mol/l) on the release of irTSH provoked by TRH (10 nmol/l), VIP (10 nmol/l) and forskolin (100 \g=m\mol /l ) were substantially reversed (P<0\m=.\01)by a specific monoclonal anti-LC1 antibody, while an isotype-matched control antibody was without effect.
present study, we have used an in vitro model to examine the effects of dexamethasone on the resting and pharmacologically evoked secretion of TSH by the rat anterior pituitary gland, and to show how they are influenced by inhibitors of RNA/protein synthesis. In addition, we have investigated the potential role of lipocortin 1 (LC1), a protein shown previously to contribute to glucocorticoid action in several systems, as a mediator of the glucocorticoid-induced suppression of TSH release in our in vitro preparation.
The significant (P<0\m=.\01) increases in the release of immunoreactive (ir)TSH from rat anterior pituitary tissue initiated by submaximal concentrations of TRH (10 nmol/l), vasoactive intestinal polypeptide (VIP, 10 nmol/l) or the adenyl cyclase activator, forskolin (100 \g=m\mol/l) were reduced significantly (P<0\m=.\05)by preincubation of the tissue with dexamethasone (0\m=.\1 \ g=m\ mol / l ) . In contrast, irTSH secretion evoked by a submaximal concentration of the L-Ca2+ channel opener BAY K8644 (10 \g=m\mol/l) was unaffected by the steroid, although readily antagonised (P<0\m=.\01)by nifedipine (1\p=n-\100 \g=m\mol/l). Inclusion of actinomycin D (1\m=.\78\g=m\mol/l) or cycloheximide (0\m=.\8\g=m\mol/l), inhibitors of RNA and protein synthesis respectively, in the medium effectively abrogated the inhibitory effects of dexamethasone (0\m=.\1\g=m\mol/l) on the secretory responses to TRH (10 nmol/l), VIP (10 nmol/l) and forskolin (100 \g=m\mol/l). pool. Progesterone (0\m=.\1\g=m\mol/l) and aldosterone ( 0\ m=. \ 1 \g=m\mol/l) were also weakly active in this regard, but thyroxine and tri-iodothyronine (0\ m=. \ 1 \g=m\mol/l) were not. Addition of an N-terminal LC1 fragment, LC1(1\p=n-\188)(0\ m=. \ 05\ p=n-\ 0\ m=. \ 53pmol/l) to the incubation medium reduced significantly (P<0\m=.\01) the increases in irTSH release induced by TRH (10 nmol/l), VIP (10 nmol/l) and forskolin (100 \ g = m\ mo l / l ) , but failed to influence (P<0\m=.\05) those initiated by BAY K8644 (10 \g=m\mol / 1). Furthermore, the inhibitory actions of dexamethasone (0\m=.\1\g=m\mol/l) on the release of irTSH provoked by TRH (10 nmol/l), VIP (10 nmol/l) and forskolin (100 \g=m\mol /l ) were substantially reversed (P<0\m=.\01)by a specific monoclonal anti-LC1 antibody, while an isotype-matched control antibody was without effect.
The results show clearly that dexamethasone, a semisynthetic glucocorticoid, acts at the pituitary level to inhibit the neurochemically evoked release of irTSH. They also provide novel evidence that the inhibitory actions of the steroid are dependent upon de novo RNA/ protein synthesis and that they involve an LC1 dependent mechanism. journal of Endocrinology (1995) (Brabant et al. 1987 , Vinge et al. 1993 , Kjellman et al. 1993 , Samuels et al. 1994 , the circadian excursion in TSH release (Nicoloff et al. 1970 , Brabant et al. 1987 ) and the TSH responses to TSHreleasing hormone (TRH) (Brown & Hedge 1974 , Pamenter & Hedge 1980 , Brabant et al. 1987 , Nicoloff & Spencer 1992 . Endogenous glucocorticoids are also effective in this regard. Thus, the elevations in serum corticosterone/cortisol evident in stress (Zaloga et al. 1985 ), Cushing's syndrome (Benker et al. 1990 , Rubello et al. 1992 ) and depression (Maes et al. 1990 (Maes et al. , 1994 (Alhquist et al. 1989 ). Thus the steroid-induced inhibition of TRH-induced TSH secretion observed in vivo (Brown 8c Hedge 1974 , Pamenter & Hedge 1980 , Brabant et al. 1987 , Nicoloff & Spencer 1992 and in vitro (Kuzuya et al. 1990) (Wallner et al. 1986 , Pepinsky et al. 1988 . LCI was initially identified as a glucocorticoid-inducible protein in peritoneal macro¬ phages (Blackwell et al. 1980 (Blackwell et al. , 1982 and has since been shown to play a critical role in the signal transduction mechanisms effecting the anti-inflammatory (Cirino et (v/v) Triton and the extract frozen and stored as above.
The protein contents of both the EDTA washes and the tissue extracts were estimated (Bradford 1976 -188) ) to mimic, and a monoclonal anti-LCI antibody (Zymedxlone Z013) to specifically reverse, the inhibitory actions of dexamethasone on the release of irTSH induced in vitro by TRH (10 nmol/1), VIP (10 nmol/1) and forskolin (100 µ /l). At concentrations of 5-3 and 53 pmol/1, LCI (1-188) caused small but significant ( <0 1) rises in basal irTSH release, but lower concentrations (0-05 and 0-53 pmol/1) were without effect (Fig. 4a) . The (Fig. Id) , they failed to modify the responses to BAY K8644 (10 pmol/l, Fig Ae) . Addition of either anti-LCI monoclonal antibody (diluted 1:15 000) or an equivalent dilution of an isotype matched control antibody (anti-spectrin +ß) to the medium had no significant effect (P>0-05 vs corresponding antiserum-free controls) on either the basal release of irTSH or the secretory responses to TRH (10 nmol/1, Fig. 5a ), VIP (10 nmol/1, Fig. 5b ) or forskolin (100 pmol/1, Fig. 5c ). Both antibodies were also without effect on basal peptide release in the presence of dexamethasone (P>0-05 vs corresponding antibody-free controls). In tissue exposed to the control antibody, as in the antibody-free controls, dexamethasone (0-1 pmol/l) effectively inhibited ( <0 1) by >75% the release of irTSH provoked by each of the three secretagogues. However, the inhibitory actions of dexamethasone (0-1 µ / ) on the release of irTSH evoked by TRH (10 nmol/1, Fig. 5a ), VIP (10 nmol/1, Fig. 5b ) and forskolin (100 pmol/1, Fig. 5c However, in support of our data, dexamethasone is known to produce marked increases in RNA/protein synthesis in our in vitro preparation within the time-frame of this study (Taylor et al. 1995a ). Furthermore, in this system, de novo protein generation is critical to the acute inhibitory effects of glucocorticoids on the secretion of both ACTH and prolactin (Taylor et al. 1993 (Taylor et al. , 1995a ) is a weak irTSH secretagogue.
The mechanisms by which LCI inhibits the secretagogue-induced release of irTSH are obscure. LCI has been implicated in the intracellular processes of mem¬ brane fusion (Francis et al. 1992 (Glaser et al. 1993) , it would provide an opportunity for interruption of the adenyl cyclase-and phospholipase C-driven cascades which trigger TSH release.
In conclusion, our results demonstrate an important role for LCI in the glucocorticoid regulation of TSH secretion and thus confirm and extend our original hypothesis that the protein serves as an important mediator of gluco¬ corticoid action not only in immune/inflammatory cells (Blackwell et al. 1982 , Cirino et al. 1989 , Perretti et al. 1993 ) but also in the brain-neuroendocrine system (Loxley et al. 1993a,/) , Taylor et al. 1993 Taylor et al. , 1995a Neuroendocrinology 62 19-31.
